A neu view of invasive lobular breast cancer

Clin Cancer Res. 2013 Jul 1;19(13):3331-3. doi: 10.1158/1078-0432.CCR-13-1031. Epub 2013 May 28.

Abstract

Genome sequencing of relapsed, invasive lobular breast cancer identified actionable mutations in 86% of the cases. HER2 alterations occur in 27% of the cases, including 4 cases with activating HER2 mutations and 1 with a novel HER2-GRB7 gene fusion. This fusion links the HER2 tyrosine kinase domain to the GRB7 src homology 2 (SH2) domain.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Breast Neoplasms / genetics*
  • Cadherins / genetics*
  • Carcinoma, Ductal, Breast / genetics*
  • Carcinoma, Lobular / genetics*
  • Female
  • Humans
  • Mutation*
  • Receptor, ErbB-2 / genetics*

Substances

  • Cadherins
  • Receptor, ErbB-2